CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
Part of Cancer clinical trials.
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced (has spread) and cannot be removed with surgery, and standard treatments have stopped working or are not available for you.
- A genetic test shows your tumor has a change in the NTRK gene or TRK protein (some groups require this, others give priority).
- You have at least one tumor that can be measured on scans (like CT or MRI).
- Your blood counts, liver and kidney function are good enough based on recent lab tests.
- You can swallow tablets (or take them crushed if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Hear when a new Solid Tumors Harboring NTRK Fusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.